AARTIDRUGS
Aarti Drugs Limited
Each stock's 10,000-path forecast, rendered as light.
Aarti Drugs Limited (AARTIDRUGS) Stock Analysis & Case Study
Is AARTIDRUGS a good buy? The data-driven verdict.
Aarti Drugs Limited (AARTIDRUGS) trades at ₹416,on the numbers it worth a closer look, a Downstox Snapshot Score of 57/100.
On the numbers, Aarti Drugs Limited (AARTIDRUGS) worth a closer look, a Downstox Snapshot Score of 57/100, weighing fairly valued at 19.7× earnings, ROE of 13.4%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AARTIDRUGS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AARTIDRUGS ranks against the 2,373 companies in our screener
- AARTIDRUGS's market cap of 3,799 Cr ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's book value of ₹170 ranks in the 68th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's promoter holding of 54.4% ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's 3-year profit (PAT) growth of 5.0% ranks in the 35th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's 3-year revenue growth of -2.0% ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's debt-to-equity ratio of 0.37x is lower than 45% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AARTIDRUGS overvalued? AARTIDRUGS P/E vs peers
AARTIDRUGS trades at 19.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
AARTIDRUGS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of AARTIDRUGS history (12%/yr drift, 37%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AARTIDRUGS 2027 | ₹271 | ₹433 | ₹693 | +4% |
| AARTIDRUGS 2028 | ₹234 | ₹451 | ₹872 | +8% |
| AARTIDRUGS 2029 | ₹211 | ₹470 | ₹1,049 | +13% |
| AARTIDRUGS 2030 | ₹192 | ₹490 | ₹1,246 | +18% |
| AARTIDRUGS 2031 | ₹178 | ₹510 | ₹1,464 | +23% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AARTIDRUGS goes up, or doubles?
The bull case for AARTIDRUGS
- AARTIDRUGS's P/E of 19.7x is lower than 63% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AARTIDRUGS's return on equity of 13.4% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,049.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹211.
AARTIDRUGS volatility & expected range, how bumpy is the ride?
Over the last 9.8 years AARTIDRUGS compounded at 12%/year with annualized volatility of 37%. That volatility implies a 1-year 80% range of ₹271-₹693, the honest backbone behind any single price target.
AARTIDRUGS price forecast, the full 60-month probability fan
AARTIDRUGS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AARTIDRUGS hits common targets within the simulated horizon?
Full multi-horizon detail on the AARTIDRUGS price target & forecast page.
AARTIDRUGS Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AARTIDRUGS scores 5/8, mixed financial health.
AARTIDRUGS MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy AARTIDRUGS with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 31.27% | 3.2× |
| Groww | 31.38% | 3.2× |
| DhanCHEAPEST | 31.27% | 3.2× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 31.42% | 3.2× |
| Pocketful | 31.52% | 3.2× |
| Fyers | 50.00% | 2.0× |
| Anand Rathi | 31.27% | 3.2× |
| Bajaj Broking | 40.00% | 2.5× |
| Share India | 31.38% | 3.2× |
Compare every broker on the AARTIDRUGS MTF page.
About Aarti Drugs Limited: sector, index & market-cap context
Aarti Drugs Limited (AARTIDRUGS) is a small-cap NSE-listed company, with a market capitalisation of ₹3,799 Cr. See more stocks on our screener.
How the AARTIDRUGS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Aarti Drugs Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AARTIDRUGS analysis, FAQs
Is Aarti Drugs Limited (AARTIDRUGS) a good buy?
On the numbers, Aarti Drugs Limited (AARTIDRUGS) worth a closer look, a Downstox Snapshot Score of 57/100, weighing fairly valued at 19.7× earnings, ROE of 13.4%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AARTIDRUGS overvalued or undervalued?
AARTIDRUGS trades at 19.7× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the AARTIDRUGS share price target for 2031?
AARTIDRUGS's probability-weighted 2031 median target is ₹510, with an 80% range of ₹178-₹1,464 (10,000-path Monte-Carlo).
What is the probability AARTIDRUGS doubles in 5 years?
The modelled probability of AARTIDRUGS reaching ₹832 (2×) within 5 years is 28%.
What is the bull case for AARTIDRUGS?
AARTIDRUGS's P/E of 19.7x is lower than 63% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AARTIDRUGS's return on equity of 13.4% ranks in the 65th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in AARTIDRUGS?
No model or past record guarantees future returns, treat this as one input, not a decision.